MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinson’s"

  • MDS Virtual Congress 2021

    Model Innovation in Parkinson’s disease drug development: linking Quantitative Systems Pharmacology to the patient voice

    J. Barrett, B. Piccoli, M. Muller, K. Barrett, D. Goncharov, C. Kaddi, K. Azer, K. Romero, D. Stephenson (Tucson, USA)

    Objective: There is a growing sense of urgency to integrate the voice of the patient in drug development in Parkinson’s disease (PD). Public private partnerships…
  • MDS Virtual Congress 2021

    Direct Costs of patients with Parkinson’s Disease in a region of the Brazilian Amazon

    R. Feio, T. França, A. Passos, A. Silva, A. Escudeiro, B. Koshimoto, D. Moura, B. Lobato (Belém, Brazil)

    Objective: To evaluate the perception of the annual direct costs (medications, medical appointments, rehabilitation, transportation) associated with the treatment for patients with PD in the…
  • MDS Virtual Congress 2021

    Trunk postural control in seated position on a prototype of unstable chair and the interference of cognitive and motor tasks in individuals with Parkinson disease

    H. Araújo, A. Miri, R. Volpe, M. Oliveira, R. Silva Jr, S. Smaili (Londrina, Brazil)

    Objective: To analyze trunk balance control of individuals with Parkinson disease (PD) in seated position and compare the control position with motor and cognitive tasks.…
  • MDS Virtual Congress 2021

    The EPSILON (Early ParkinSon wIth L-dopa/DDCi and OpicapoNe) study in early Parkinson’s disease: design and rationale of a phase III, double-blind, randomized, placebo-controlled study

    J. Ferreira, W. Poewe, O. Rascol, F. Stocchi, A. Antonini, J. Moreira, J. Rocha, P. Soares-da-Silva (Lisbon, Portugal)

    Objective: This study aims to explore the potential of opicapone (OPC) to enhance the clinical benefit of levodopa (L-dopa)/dopa decarboxylase inhibitor (DDCi) in patients with…
  • MDS Virtual Congress 2021

    CVT-301 (levodopa inhalation powder): meta-analysis of safety in patients with Parkinson’s disease (PD)

    P. Lewitt, P. Zhao, A. Corbin, D. Kegler-Ebo, B. Blank (West Bloomfield, USA)

    Objective: Safety results from a phase 3, double-blind study of CVT-301 in patients with PD were combined with results from a 4-week, phase 2b, double-blind,…
  • MDS Virtual Congress 2021

    Therapy to Reduce dementia risk In Parkinson’s disease (TRIP): Proof-of-concept trial

    D. Pourzinal, A. Bakker, G. Byrne, K. Mcmahon, J. O'Sullivan, R. Adam, A. Lehn, D. Copland, J. Yang, G. Pontone, T. Au, R. Littleford, M. Chatfield, Z. Mari, N. Dissanayaka (Herston, Australia)

    Objective: The TRIP proof-of-concept study examines functioning of the hippocampal DG/CA3 subregion as a biomarker and therapeutic target for memory impairment in Parkinson’s Disease (PD).…
  • MDS Virtual Congress 2021

    The effect of medical xenon on patients with advanced stages of the Parkinson’s disease with motor fluctuations

    R. Bogdanov, E. Vasilchenko, A. Dobrovolsky, P. Ratmanova, D. Napalkov, V. Bogin (Moscow, Russian Federation)

    Objective: The aim of the study to increase the effectiveness of pharmacotherapy in patients with advanced stages of Parkinson's disease (PD) with motor fluctuations, using…
  • MDS Virtual Congress 2021

    Survey-Based study of marijuana used in Parkinson’s Disease patients

    R. Healy, J. Paulson, A. Deb, K. Smith (Worcester, USA)

    Objective: A survey based assessment of marijuana use in patients with Parkinson’s disease. Background: Due to marijuana’s controlled status little quality research and no clear…
  • MDS Virtual Congress 2021

    Influence of demographic characteristics on the effectiveness of opicapone in Parkinson’s disease patients with motor fluctuations: findings from the real-world OPTIPARK study

    B. Mohamed, A. Lees, H. Reichmann, D. Martins, D. Magalhães, J. Rocha, P. Soares-da-Silva (Cardiff, United Kingdom)

    Objective: This post-hoc analysis evaluated the influence of baseline demographic characteristics (i.e., age and gender) on the response to opicapone (OPC) in Parkinson’s disease (PD)…
  • MDS Virtual Congress 2021

    Problems faced by Parkinson’s disease patients during COVID-19 pandemic compulsory lockdown and its management with the help of Telemedicine in a North Indian cohort

    K. Shukla, N. Sawal (Chandigarh, India)

    Objective: To study problems faced by PD patients during lockdown due lack of healthcare and medication procurement and address such problems using telemedicine via virtual…
  • « Previous Page
  • 1
  • …
  • 433
  • 434
  • 435
  • 436
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • AI-Powered Detection of Freezing of Gait Using Wearable Sensor Data in Patients with Parkinson’s Disease
    • Effect of marijuana on Essential Tremor: A case report
    • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Covid vaccine induced parkinsonism and cognitive dysfunction
    • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
    • Patients with Essential Tremor Live Longer than their Relatives
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley